Hyperthyroidism Treatment in India & UAE — Medical & Surgical Care from $500
Hyperthyroidism treatment in India from $500. Antithyroid drugs, radioiodine therapy & thyroidectomy by expert endocrine surgeons. 96% success. Book with GAF Healthcare.
Estimated cost: $500 – $4,000 · Average stay: 1–5 days
Hyperthyroidism is a condition in which the thyroid gland — a butterfly-shaped gland at the base of the neck — produces excessive quantities of thyroxine (T4) and triiodothyronine (T3), the hormones that regulate the body's metabolism. This hormonal excess accelerates virtually every metabolic process in the body, causing a constellation of symptoms that range from mildly disruptive to life-threatening in severe, untreated cases.
The most common cause of hyperthyroidism worldwide is Graves' disease — an autoimmune condition in which the immune system produces thyroid-stimulating immunoglobulins (TSIs) that bind to TSH receptors on the thyroid gland, continuously stimulating thyroid hormone production. Graves' disease accounts for 70–80% of all hyperthyroidism. Other important causes include toxic multinodular goitre (several autonomously functioning nodules within an enlarged thyroid gland), toxic adenoma (a single autonomously functioning nodule), and subacute thyroiditis (inflammatory release of stored thyroid hormone, usually self-limiting).
Hyperthyroidism classically causes: unexplained weight loss despite increased appetite; heat intolerance and excessive sweating; palpitations (often atrial fibrillation in older patients); tremor; anxiety and irritability; fatigue; frequent bowel movements; menstrual irregularity; and in Graves' disease specifically, exophthalmos (protrusion of the eyeballs) from inflammatory swelling of the orbital contents — a pathognomonic feature. Thyroid storm — a rare, life-threatening exacerbation — requires immediate intensive care management.
India and the UAE have expert endocrinology, nuclear medicine, and endocrine surgery departments that manage the complete spectrum of hyperthyroidism — from initial diagnosis and medical management through to radioiodine therapy and definitive thyroidectomy.
Diagnosing Hyperthyroidism
Hyperthyroidism is diagnosed biochemically: TSH (thyroid-stimulating hormone) is suppressed below the normal range (often undetectable); free T4 (fT4) and/or free T3 (fT3) are elevated. The degree of TSH suppression and fT4/fT3 elevation grade the severity: subclinical hyperthyroidism (suppressed TSH with normal fT4/fT3); overt hyperthyroidism (suppressed TSH with elevated fT4 or fT3).
Additional investigations identify the underlying cause: thyroid antibodies (TSH receptor antibodies — TRAb — positive in Graves' disease; TPO antibodies are non-specific); thyroid ultrasound (assessing gland size, nodularity, vascularity — Graves' shows a diffusely enlarged, hypervascular gland); radionuclide thyroid scan (technetium-99m or I-123 — Graves' shows diffuse increased uptake; toxic adenoma shows a 'hot nodule' with suppression of the rest of the gland; toxic multinodular goitre shows patchy increased uptake). Thyroid eye disease (Graves' ophthalmopathy) is assessed with ophthalmology review and orbital MRI.
Treatment Options
Three definitive treatment options exist for hyperthyroidism: antithyroid drugs, radioiodine therapy, and surgery. The choice depends on the underlying cause, disease severity, patient age, presence of thyroid eye disease, gland size, nodularity, and patient preference.
Antithyroid drugs (ATDs) — carbimazole (methimazole) or propylthiouracil (PTU) — are the first-line treatment for Graves' disease, particularly in younger patients. They block thyroid hormone synthesis without damaging the gland. ATDs achieve remission (sustained euthyroidism after withdrawal) in approximately 40–60% of Graves' disease patients after 12–18 months of treatment. Relapse after ATD discontinuation is common (50–60%); definitive treatment (radioiodine or surgery) is then offered.
Radioiodine therapy (I-131) is a safe, effective, and highly convenient treatment. A calculated oral dose of radioactive iodine is given as a capsule or liquid; the thyroid gland concentrates the iodine (as it does with dietary iodine) and is progressively destroyed by the beta radiation emitted. Most patients require only one dose; hypothyroidism (the expected outcome of ablative doses) then requires lifelong thyroxine replacement. Radioiodine is contraindicated in pregnancy and is used with caution in active thyroid eye disease (as it can transiently worsen ophthalmopathy).
Total thyroidectomy provides immediate, definitive treatment — particularly preferred for: large goitres causing compressive symptoms (dysphagia, stridor); suspicion of thyroid malignancy (nodules requiring biopsy); patients who prefer immediate resolution of hyperthyroidism with avoidance of radioiodine; active severe Graves' ophthalmopathy (where radioiodine is contraindicated); and toxic multinodular goitre where radioiodine may require very large doses.
Procedure Steps
- TFT (TSH, fT4, fT3); TRAb; TPO antibodies; thyroid ultrasound; radionuclide scan
- ATD therapy initiated to achieve euthyroidism; beta-blocker for symptomatic relief
- Treatment option chosen: continue ATD for 12–18 months (Graves') OR radioiodine OR thyroidectomy
- Pre-thyroidectomy: euthyroidism achieved; iodine (Lugol's) given 10 days pre-op to reduce vascularity
- Total thyroidectomy under general anaesthesia; parathyroid identification and preservation
- Post-thyroidectomy: thyroxine replacement commenced; calcium and PTH monitored (hypoparathyroidism surveillance)
- Long-term: TFT monitoring 6–8 weekly initially; TRAb at 12–18 months (Graves' remission assessment)
Cost Comparison Worldwide
Country — Range — Savings
--- — --- — ---
USA — $8,000 – $20,000 (thyroidectomy) — Save up to 85%
UK — £3,000 – £10,000 (private) — Save up to 75%
UAE — $3,000 – $10,000 — Save up to 65%
India — $500 – $4,000 — Best value
Medical management (ATDs) in India costs $300–$800 per year including consultations and monitoring blood tests. Radioiodine therapy costs $300–$600 per treatment. Total thyroidectomy for hyperthyroidism in India costs $2,500–$4,000 all-inclusive. The equivalent private thyroidectomy in the USA costs $15,000–$25,000. India's endocrine surgery departments combine endocrine expertise with significantly lower costs.
Recovery & Follow-up
Recovery from medical management is not a surgical recovery — euthyroidism is typically achieved within 4–8 weeks of starting ATDs. Radioiodine recovery: the patient avoids close contact with pregnant women and children for 1–2 weeks; thyroid hormone levels normalise (often via transient hyperthyroidism before hypothyroidism) over 6–12 weeks. Thyroidectomy recovery: hospital discharge day 1–2; return to normal activities at 2 weeks; calcium supplementation if transient hypoparathyroidism detected. Lifelong thyroxine (typically levothyroxine 75–150 mcg daily) is required after total thyroidectomy and most radioiodine ablations.
Recovery Tips
- Take antithyroid drugs at the same time every day and do not miss doses
- Report any sore throat, fever, or mouth ulcers on ATDs immediately — agranulocytosis is a rare but serious complication
- After thyroidectomy, take the prescribed calcium supplements for the first 2–4 weeks until parathyroid function is confirmed
- Commence thyroxine replacement within 24 hours of thyroidectomy — do not delay
- Avoid iodine-rich foods (kelp, seaweed, iodised salt in large quantities) during antithyroid drug treatment
Risks & Complications
ATD risks: agranulocytosis (rare — 0.2–0.5%; presents as sore throat and fever; requires immediate blood count); liver toxicity (rare, more with PTU); skin rash; and drug failure with relapse. Radioiodine risks: transient worsening of hyperthyroidism; development or worsening of Graves' ophthalmopathy (managed with concurrent oral corticosteroids); hypothyroidism (the expected long-term outcome); and theoretical radiation risk (extremely low in practice). Thyroidectomy risks: recurrent laryngeal nerve injury causing voice hoarseness (permanent — 1%; temporary — 3–5%); hypoparathyroidism and hypocalcaemia (temporary — 5–10%; permanent — 1–2%); haematoma requiring return to theatre; and infection.
Why GAF Healthcare
GAF Healthcare connects patients with India's endocrinology and endocrine surgery centres where all three treatment options are available — allowing the most appropriate treatment to be selected based on the patient's individual clinical, social, and personal factors. TFT, TRAb, and ultrasound results can be reviewed digitally before travel, and a full treatment plan confirmed.
Frequently Asked Questions
Which treatment is best for Graves' disease?
All three options (ATDs, radioiodine, thyroidectomy) are effective for Graves' disease. The choice is highly individual. Younger patients in their first episode of Graves' disease are typically offered ATDs for 12–18 months, aiming for remission. Patients who relapse after ATDs are offered radioiodine or thyroidectomy. Radioiodine is preferred for older patients, smaller glands, and those without active thyroid eye disease. Surgery is preferred for large goitres, coexisting thyroid nodules requiring biopsy, severe ophthalmopathy, active thyroid malignancy, or when immediate definitive treatment is desired.
Will I need to take medication for life after hyperthyroidism treatment?
After radioiodine ablation or total thyroidectomy, the thyroid gland no longer functions and lifelong thyroxine (T4) replacement is required — taken as a daily tablet. After successful ATD-induced remission of Graves' disease (approximately 40–60% of patients), no ongoing medication is needed, though TFT monitoring every 6–12 months is recommended to detect relapse. Most patients who achieve remission remain euthyroid for many years, though late relapse can occur.
Is hyperthyroidism dangerous if untreated?
Yes. Untreated overt hyperthyroidism carries significant risks: atrial fibrillation (with embolic stroke risk); heart failure; bone loss (osteoporosis from increased bone turnover); and thyroid storm — a rare but potentially fatal acute exacerbation caused by marked thyroid hormone excess, presenting with high fever, extreme agitation, vomiting, diarrhoea, and cardiac arrhythmias. Even subclinical hyperthyroidism (suppressed TSH with normal fT4/fT3) carries a 2–3-fold increased risk of atrial fibrillation and should be monitored or treated.